Comparison of ER, PR & HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer

Asian Pacific Journal of Cancer Prevention

Volumn 9, Issue 4, 2008, Pages 553-556

  Azizun Nisa, ^a   Bhurgri, Yasmin ^a   Raza, Farrukh ^a   Kayani, Naila ^a  

^a NONE

Author keywords

Biological behaviour; Breast cancer; Prognosis; Receptor status

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER INVASION; CANCER STAGING; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPH NODE METASTASIS; MASTECTOMY; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEEDLE BIOPSY; PAGET NIPPLE DISEASE; PAKISTAN; PATHOLOGY; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; SURVIVAL; TISSUE CULTURE TECHNIQUE;

ADULT; AGED; BIOPSY, NEEDLE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY, MODIFIED RADICAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PAKISTAN; PROBABILITY; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TISSUE CULTURE TECHNIQUES; TUMOR MARKERS, BIOLOGICAL;

EID: 66149150268     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Barnes DM, Hanby AM (2001). Oestrogen and progesterone receptors in breast cancer: past, present and future. Histopathology, 38, 271-4.
2. Bhurgri Y, Kayani N, Faridi N, et al (2007). Patho-epidemiology of breast cancer in Karachi '1995-1997'. Asian Pac J Cancer Prev, 8, 215-20.
3. Carlomagno C, Perrone F, Gallo C, et al (1996). c-erb B2 over-expression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol, 14, 2702-8.
4. Fatima S, Faridi N, Gill S (2005). Breast cancer. Steroid receptors and other prognostic indicators. J Coll Physicians Surg, 15, 230-3
5. Fisher ER, Redmond CK, Liu H, Rockette H, Fisher B (1980). Correlation of estrogen receptor and pathologic characteristics of invasive breast cancer. Cancer, 45, 349-53.
6. Hilf R, Feldstein ML, Savlov ED, Gibson SL, Seneca B (1980). The lack of relationship between estrogen receptor status and response to chemotherapy. Cancer, 46 (12 Suppl), 2797-800.
7. Hung MC, Lau YK (1999). Basic science of HER-2/neu: a review. Semin Oncol, 26 (4 Suppl 12), 51-9.
8. Lal P, Tan LK, Chen B (2005). Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol, 123, 541-6.
9. Maynard PV, Davies CJ, Blamey RW, et al (1978). Relationship between oestrogen-receptor content and histological grade in human primary breast tumours. Br J Cancer, 38, 745-8.
10. McGuire WL, Clark GM (1983). The prognostic role of progesterone receptors in human breast cancer. Semin Oncol, 10 (4 Suppl 4), 2-6.
11. Mori I, Yang Q, Kakudo K (2002). Predictive and prognostic markers for invasive breast cancer. Pathol Int, 52, 186-94.
12. Naqvi SQH, Jamal Q, Mahmood RK, Zaidi SMH, Abbas F (2002). Significance of HER-2/ neu oncoprotien overexpression on node positive invasive breast cancer. J Coll Physicians Surg, 12, 534-7
13. Parkin DM, Bray F, Ferlay J, Pisani P (2001). Estimating the world cancer burden: Globocan 2000. Int J Cancer, 94, 153-6.
14. Rampaul RS, Pinder SE, Elaston CW, Ellis IO (2001). Prognostic and predictive factors in primary breast cancer and their role in patient management; the Nottingham breast team. Eur J Surg Oncol, 27, 229-38
15. Rilke F, Colnaghi MI, Cascinelli N, et al (1991). Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer, 49, 44-9.
16. Samur M, Karaveli S, Bozcuk H, et al (2003). A novel method of reporting c-erb B2 over-expression: Correlation with grade but not with other prognostic parameters in breast cancer. Turk J Med Sci, 33, 363-8.
17. Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82.
18. Suo Z, Risberg B, Karlsson MG, et al (2002). The expression of EGFR family ligands in breast carcinomas. Int J Surg Pathol, 10, 91-9.
19. Tsuda H, Hirohashi S, Hirota T, Shimosato (1991). Alterations in copy number of c-erbB-2 and c-myc proto-oncogenes in advanced stage of human breast cancer. Acta Pathol Jpn, 41, 19-23.
20. Yamauchi H, Stearns V, Hayes DF (2001). When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol, 19, 2334-56.
21. Zeillinger R, Kury F, Czerwenka K, et al (1989). HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene. 4, 109-14.